|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.07 USD | +0.75% |
|
-0.60% | -22.14% |
The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for hemophilia A, the company said, giving patients with the inherited bleeding disorder an option to reduce regular blood infusions. (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,798 PTS | +0.92% | +1.57% | - | ||
| 281.3 AUD | +0.44% | +0.25% | 89.87B | ||
| 231 CHF | +0.02% | +0.65% | 206B | ||
| 129.8 USD | +4.38% | +5.12% | 12.27B | ||
| 75.07 USD | +0.75% | -0.60% | 14.25B | ||
| 28.66 USD | +1.63% | -0.76% | 162B | ||
| 0.5644 USD | +2.69% | -5.17% | 117M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -22.14% | 14.25B | |
| -1.85% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +62.48% | 26.47B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +6.03% | 9.11B | |
| -19.53% | 7.32B |
BIOMARIN PHARMACEUTICAL INC. 
